Get the Stockscreener App
0.92
2.13%
-0.02
After Hours:
.93
0.01
+1.09%
Artelo Biosciences Inc stock is traded at $0.92, with a volume of 24,392.
It is down -2.13% in the last 24 hours and down -5.15% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$0.94
Open:
$0.9349
24h Volume:
24,392
Relative Volume:
0.06
Market Cap:
$3.02M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-0.2911
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
-9.80%
1M Performance:
-5.15%
6M Performance:
-11.54%
1Y Performance:
-32.35%
1-Day Range:
$0.91
$0.935
1-Week Range:
$0.91
$1.04
52-Week Range:
$0.8196
$1.5899
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
0.92 | 3.35M | 0 | -9.60M | -8.96M | -3.16 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
ARTELO BIOSCIENCES, INC. SEC 10-Q Report - TradingView
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Artelo Biosciences (ARTL) Expected to Announce Earnings on Monday - Defense World
Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Artelo Biosciences (ARTL) Reports Promising Psoriasis Treatment Advances | ARTL Stock News - GuruFocus
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models - AOL.com
Artelo Biosciences Announces Publication of New Peer-Reviewed Re - GuruFocus
Artelo Biosciences Reports Positive Effects Of ART26.12 In Psoriasis Models - Nasdaq
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis | ARTL Stock News - GuruFocus
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis - The Manila Times
Artelo Biosciences Announces Positive Preclinical Results for Psoriasis Treatment ART26.12 in Journal of Investigative Dermatology - Nasdaq
Breakthrough Oral Psoriasis Treatment Matches Current Drugs in New Research, Phase 1 Results Coming - Stock Titan
Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Grows By 58,220.0% - Defense World
Artelo Biosciences (NASDAQ:ARTL) Shares Down 11.2% – What’s Next? - Defense World
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Advances Novel Pain Therapy with Upcoming Data - GuruFocus
Artelo Biosciences (ARTL) Advances Cancer Therapy Pipeline - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ARTL stock touches 52-week low at $0.85 amid market challenges - Investing.com
D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Artelo Biosciences stock hits 52-week low at $0.91 - Investing.com
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 - The Manila Times
New Data Reveals Artelo's FABP5 Inhibitor Could Transform Pain and Cancer Treatment - Stock Titan
Artelo Biosciences (ARTL) Projected to Post Earnings on Monday - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
HC Wainwright Has Pessimistic View of ARTL FY2025 Earnings - Defense World
Artelo Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks
Artelo Biosciences (NASDAQ:ARTL) Given Buy Rating at HC Wainwright - Defense World
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results - The Manila Times
ARTELO BIOSCIENCES, INC. SEC 10-K Report - TradingView
Can Artelo's Three Clinical Programs Overcome Its $9.8M Annual Loss? - StockTitan
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Increase in Short Interest - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Artelo Biosciences reports promising nonclinical CBD study - MSN
Analyzing Artelo Biosciences (NASDAQ:ARTL) & Rafael (NYSE:RFL) - Defense World
Artelo Biosciences Reports Positive ART12.11 Tablet Data Showing Improved Pharmacokinetics - Nasdaq
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - GlobeNewswire
Revolutionary CBD Tablet Formulation Achieves Breakthrough Pharmacokinetic Results vs Epidiolex - StockTitan
Artelo Biosciences to Present its New Data on ART12.11 - GlobeNewswire
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland - The Manila Times
Artelo's CBD Innovation Matches Epidiolex PerformanceGroundbreaking Study Revealed - StockTitan
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium - Marketscreener.com
Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Drops By 42.2% - Defense World
Drug Designed to Treat Neuropathy Advances in Clinical Trials - Stony Brook University
Artelo Biosciences (NASDAQ:ARTL) Earns Buy Rating from D. Boral Capital - Defense World
Aemetis, Inc. (NASDAQ:AMTX) Holdings Trimmed by Jane Street Group LLC - Defense World
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - The Manila Times
Artelo Biosciences Completes First Phase 1 Cohort for Novel FABP5 Pain Treatment ART26.12 - StockTitan
EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program - Benzinga
Artelo Biosciences Holds Annual Meeting; Directors Re-Elected and Independent Auditor Appointment Ratified - Defense World
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):